Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.88 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 6/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829420 | 1.00 | METTL3 (0.88) | METTL3GAAEGFRMAPTCFD | |
| SCHEMBL13693054 | 0.94 | METTL3 (0.86) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL13942147 | 0.94 | METTL3 (0.86) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL13596336 | 0.93 | METTL3 (0.77) | METTL3GAAEGFRMAPTCFD | |
| Elvitegravir SCHEMBL29623981 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL726251 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL726252 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| Elvitegravir SCHEMBL13225651 | 0.93 | METTL3 (1.00) | METTL3GAAEGFRMAPTPLA2G4A | |
| SCHEMBL11948686 | 0.93 | METTL3 (0.76) | METTL3GAAEGFRMAPTCFD | |
| Elvitegravir SCHEMBL1050769 | 0.93 | METTL3 (0.98) | METTL3GAAEGFRMAPTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150810-A1 | TABLETS FOR COMBINATION THERAPY | GILEAD SCIENCES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8759525-B2 | Process and intermediates for preparing integrase inhibitors | Gilhead Sciences, Inc. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8633219-B2 | Combination therapy | JAPAN TOBACCO INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130203791-A1 | Tablets and Preparation Thereof | ABBVIE INC (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440831-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8420821-B2 | Process for production of 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8383819-B2 | Method for producing 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8153801-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100285122-A1 | TABLETS FOR COMBINATION THERAPY | GILEAD SCIENCES, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-7825252-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090233964-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20070219243-A1 | Method for improving the pharmacokinetics of HIV integrase inhibitors | JAPAN TOBACCO, INC. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099366-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
| US-20090233964-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | APOBEC3C, TMPRSS15, APOBEC3G | METTL3 2482/4885GAA 249/4885EGFR 3430/4885 |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
| US-20080125594-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
| US-20100292480-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
| US-20100285122-A1 | TABLETS FOR COMBINATION THERAPY | SLC5A6, SLC5A2, SLC5A1 | METTL3 3141/4885GAA 2701/4885EGFR 1663/4885 |
| US-20070219243-A1 | Method for improving the pharmacokinetics of HIV integrase inhibitors | SI, APOBEC3C, TMPRSS15 | METTL3 2682/4885GAA 251/4885EGFR 3370/4885 |
| US-20150150810-A1 | TABLETS FOR COMBINATION THERAPY | SLC5A6, SLC5A2, SLC5A1 | METTL3 3141/4885GAA 2701/4885EGFR 1663/4885 |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | METTL3 938/4885GAA 2926/4885EGFR 4526/4885 |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | METTL3 2511/4885GAA 1763/4885EGFR 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.